Harwood Feffer LLP Announces Investigation of Salix Pharmaceuticals Ltd.

NEW YORK, Nov. 7, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Salix Pharmaceuticals Ltd. ("Salix" or the "Company") (NASDAQ: SLXP), concerning whether the board has breached its fiduciary duties to shareholders.

On November 6, 2014, the Company announced poor quarterly results and that its chief financial officer had resigned.  During a subsequent conference call with investors to discuss the quarterly results, a Company representative disclosed that the Audit Committee of Salix's Board of Directors is investigating the Company's reporting of inventory levels.

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own Salix shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
                                (212)935-7400
Email:  bsachsmichaels@hfesq.com
Website:   http://www.hfesq.com 
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm. 

The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

SOURCE Harwood Feffer LLP